$AKBA News

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target

Akebia Therapeutics, U.S. Renal Care Announce U.S. Renal Care Kidney Research Proposed To Halt Vafseo Outcomes In Center Experience Study After Planned Interim Analysis Based On Recommendation From Independent Data Monitoring Committee, Trial Steering Committee

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

Akebia Therapeutics Granted New Patent And Listed In Orange Book; Notified Of Eligibility To Extend Expiration Of Composition Of Matter Patent Covering Vafseo

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results

Akebia (AKBA) Q1 2026 Earnings Transcript

Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript

Akebia Therapeutics Q1 Earnings Call Highlights

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics Q1 EPS $(0.03), Inline, Sales $53.544M Beat $51.668M Estimate

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Akebia Therapeutics Announces Publication Of Post-Hoc Win Statistics Analysis Of All-Cause Mortality And Hospitalization From Its Global Phase 3 INNO2VATE Program In The Journal Of The American Society Of Nephrology

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock?

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Akebia Therapeutics Doses First Patient In Phase 1 Clinical Study Of AKB-9090 To Treat Cardiac Surgery-Associated Acute Kidney Injury